Compugen to Participate in November Investor Conferences

Compugen (CGEN) announced that management will participate in the Stifel and Jefferies healthcare investor conferences in November 2026.

Rhea-AI Summary

Compugen (CGEN) announced that management will participate in the Stifel and Jefferies healthcare investor conferences in November 2026.

The Stifel conference in New York includes a fireside chat on November 10 at 11:20 am ET and one-on-one meetings. Management will hold one-on-one meetings at the Jefferies conference in London on November 18–19. A live webcast of the fireside chat will be available on Compugen's investor relations events page, with a replay afterward.

Key Terms

bispecific antibody, adaptive platform trial

2 terms

bispecific antibody medical

"a PD-1/TIGIT bispecific antibody"

A bispecific antibody is a specially designed protein that can attach to two different targets at the same time. Think of it as a custom-made connector that brings two things together—such as a disease cell and an immune system component—helping the body fight illnesses more effectively. For investors, understanding bispecific antibodies is important because they represent innovative therapies that could lead to new treatments and potentially lucrative market opportunities.

adaptive platform trial medical

"blinded randomized ovarian cancer adaptive platform trial"

An adaptive platform trial is a flexible clinical study design that tests multiple treatments at once and adjusts which drugs, doses, or patient groups are pursued as results come in. Think of it like a single kitchen testing several recipes and quickly favoring the ones that work while dropping or changing the others — this can speed development, cut costs, and reduce risk for investors by identifying winners and failures faster than traditional one-at-a-time trials.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOLON, Israel, Nov. 3, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in the following upcoming investor conferences in November 2026:

Stifel 2026 Healthcare Conference
Date: Tuesday, November 10, 2026
Location: New York, NY
Format: Fireside chat and 1x1 meetings
Fireside chat time: 11:20 am ET

2026 Jefferies Global Healthcare Conference 
Date: Wednesday and Thursday, November 18-19, 2026
Location: London, UK
Format: 1x1 meetings

Please contact your Stifel or Jefferies representative for additional information or to schedule a meeting with Compugen.

A live webcast of the fireside chat will be available on the events page of the Investor Relations section of Compugen's website at www.cgen.com. A replay will be available following the live event.

About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI-powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, is currently being evaluated in a blinded randomized ovarian cancer adaptive platform trial as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902, Compugen's anti-TIGIT antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen has an early-stage immuno-oncology pipeline that consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company Contact:
Lindsey Trickett
Head of Investor Relations and Corporate Communications
Email: lindseyt@cgen.com
Tel: +1 (628) 241-0071

View original content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-november-investor-conferences-302927594.html

SOURCE Compugen Ltd.